Black Rock Inc. Chinook Therapeutics, Inc. Transaction History

Black Rock Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$18.66 - $38.58 $5.98 Million - $12.4 Million	320,702 Added 8.13%	4,263,241 $164 Million
Q1 2023 May 12, 2023	SELL	$21.53 - $26.8 $262,709 - $327,013	-12,202 Reduced 0.31%	3,942,539 $91.3 Million
Q4 2022 Feb 13, 2023	BUY	$18.63 - $27.35 $5.65 Million - $8.3 Million	303,442 Added 8.31%	3,954,741 $104 Million
Q3 2022 Nov 14, 2022	BUY	$17.51 - $23.37 $5.59 Million - $7.46 Million	319,169 Added 9.58%	3,651,299 $71.8 Million
Q2 2022 Aug 12, 2022	BUY	$12.59 - $18.8 $3.49 Million - $5.21 Million	277,133 Added 9.07%	3,332,130 $58.3 Million
Q1 2022 May 12, 2022	BUY	$12.02 - $16.69 $806,133 - $1.12 Million	67,066 Added 2.24%	3,054,997 $50 Million
Q4 2021 Feb 10, 2022	BUY	$10.69 - $16.83 $4.82 Million - $7.59 Million	450,705 Added 17.76%	2,987,931 $48.7 Million
Q3 2021 Nov 09, 2021	BUY	$11.5 - $14.86 $767,705 - $992,009	66,757 Added 2.7%	2,537,226 $32.4 Million
Q2 2021 Aug 11, 2021	BUY	$13.6 - $18.98 $33.6 Million - $46.9 Million	2,470,469 New	2,470,469 $34.9 Million

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.